FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164701460> ?p ?o ?g. }

• W2164701460 endingPage "78" @default.
• W2164701460 startingPage "73" @default.
• W2164701460 abstract "Biomarkers in MedicineVol. 5, No. 1 General content - EditorialInnovative biomarker development for personalized medicine in breast cancer careGeorge C Zografos & Dimitrios H RoukosGeorge C Zografos1st Propaedeutic Surgical Department, University of Athens, Hippocration General Hospital, Athens, GreeceSearch for more papers by this author & Dimitrios H Roukos† Author for correspondenceDepartment of Surgery, Ioannina University School of Medicine, Ioannina, TK 451 10, Greece and Personalized Cancer Networks Medicine, Biobank, Ioannina University School of Medicine, Ioannina, TK 451 10, GreeceSearch for more papers by this authorPublished Online:14 Feb 2011https://doi.org/10.2217/bmm.10.116AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: breast cancercancer genomecommercializationevidencegeneticsgenomicsinnovationmolecular diagnosticsstandard markertestBibliography1 Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol.24(14),2137–2150 (2006).Crossref, Medline, Google Scholar2 Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J. Clin.60(5),277–300 (2010)Crossref, Medline, Google Scholar3 Goldhirsch A, Ingle JN, Gelber RD et al.: Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol.20(8),1319–1329 (2009).Crossref, Medline, CAS, Google Scholar4 Stafford RS, Wagner TH, Lavori PW: New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N. Engl. J. Med.361(13),1230–1233 (2009).Crossref, Medline, CAS, Google Scholar5 Ziogas D, Roukos DH: Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann. Surg. Oncol.16(7),1771–1782 (2009).Crossref, Medline, Google Scholar6 Domchek SM, Friebel TM, Singer CF et al.: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA304(9),967–975 (2010).Crossref, Medline, CAS, Google Scholar7 Welch GH: Screening mammography – a long run for a short slide? N. Engl. J. Med.363,1276–1278 (2010).Crossref, Medline, CAS, Google Scholar8 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet365(9472),1687–1717 (2005).Crossref, Medline, Google Scholar9 Huang RS, Ratain MJ: Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J. Clin.59(1),42–55 (2009).Crossref, Medline, Google Scholar10 Baselga J, Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer9(7),463–475 (2009).Crossref, Medline, CAS, Google Scholar11 Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344(11),783–792 (2001).Crossref, Medline, CAS, Google Scholar12 Burstein HJ: The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med.353(16),1652–1654 (2005).Crossref, Medline, CAS, Google Scholar13 Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S: Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist13(6),620–630 (2008).Crossref, Medline, CAS, Google Scholar14 Roukos DH: Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics11(8),1039–1043 (2010).Link, CAS, Google Scholar15 Perou CM, Sorlie T, Eisen MB et al.: Molecular portraits of human breast tumours. Nature406(6797),747–752 (2000).Crossref, Medline, CAS, Google Scholar16 Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27),2817–2826 (2004).Crossref, Medline, CAS, Google Scholar17 van de Vijver MJ, He YD, van’t Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347(25),1999–2009 (2002).Crossref, Medline, CAS, Google Scholar18 Roukos DH, Ziogas DE, Katsios C: Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. Expert Rev. Anticancer Ther.10(8),1187–1195 (2010).Crossref, Medline, CAS, Google Scholar19 Manolio TA: Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med.363(2),166–176 (2010).Crossref, Medline, CAS, Google Scholar20 Frazer KA, Ballinger DG, Cox DR et al.: A second generation human haplotype map of over 3.1 million SNPs. Nature449(7164),851–861 (2007).Crossref, Medline, CAS, Google Scholar21 Wacholder S, Hartge P, Prentice R et al.: Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med.362(11),986–993 (2010).Crossref, Medline, CAS, Google Scholar22 Annes JP, Giovanni MA, Murray MF: Risks of presymptomatic direct-to-consumer genetic testing. N. Engl. J. Med.363(12),1100–1101 (2010).Crossref, Medline, CAS, Google Scholar23 Manolio TA, Collins FS, Cox NJ et al.: Finding the missing heritability of complex diseases. Nature,461(7265),747–753 (2009).Crossref, Medline, CAS, Google Scholar24 Schadt EE: Molecular networks as sensors and drivers of common human diseases. Nature461(7261),218–223 (2009).Crossref, Medline, CAS, Google Scholar25 Roukos DH, Katsios C, Liakakos T: Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn.10(5),541–545 (2010).Crossref, Medline, CAS, Google Scholar26 Roukos DH: Systems medicine: a real approach for future personalized oncology? Pharmacogenomics11(3),283–287 (2010).Link, Google Scholar27 Ng AC: Integrative systems biology and networks in autophagy. Semin. Immunopathol.32(4),355–361 (2010).Crossref, Medline, Google Scholar28 Werner T: Next generation sequencing in functional genomics. Brief Bioinform.11(5),499–511 (2010).Crossref, Medline, CAS, Google Scholar29 Heard E, Tishkoff S, Todd JA et al.: Ten years of genetics and genomics: what have we achieved and where are we heading? Nat. Rev. Genet.11(10),723–733 (2010).Crossref, Medline, CAS, Google Scholar30 Breitkreutz A, Choi H, Sharom JR et al.: A global protein kinase and phosphatase interaction network in yeast. Science328(5981),1043–1046 (2010).Crossref, Medline, CAS, Google Scholar31 Ding L, Ellis MJ, Li S et al.: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature464(7291),999–1005 (2010).Crossref, Medline, CAS, Google Scholar32 Venter JC: Multiple personal genomes await. Nature464(7289),676–677 (2010).Crossref, Medline, CAS, Google Scholar33 Roukos DH: Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J. DOI: 10.1038/tpj.2010.81 (2010) (Epub ahead of print).Medline, Google Scholar34 Barnett GC, Shah M, Redman K et al.: Risk factors for the incidence of breast cancer: do they affect survival from the disease? J. Clin. Oncol.26(20),3310–3316 (2008).Crossref, Medline, Google Scholar35 Roukos DH: Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn.10(3),247–250 (2010).Crossref, Medline, Google Scholar36 Wood SN: Statistical inference for noisy nonlinear ecological dynamic systems. Nature466(7310),1102–1104 (2010).Crossref, Medline, CAS, Google Scholar37 Hudson TJ, Anderson W, Artez A et al.: International network of cancer genome projects. Nature464(7291),993–998 (2010).Crossref, Medline, CAS, Google Scholar38 Katsnelson A: Genomics goes beyond DNA sequence. Nature465(7295),145 (2010).Crossref, Medline, CAS, Google Scholar39 Roukos DH: Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev. Med. Devices7(6),723–726 (2010).Crossref, Medline, CAS, Google Scholar40 Roukos DH: Novel clinico–genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care. Expert Rev. Mol. Diagn.10(1),33–48 (2010).Crossref, Medline, CAS, Google Scholar41 Roukos DH: Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med.4(4),583–586 (2010).Link, Google Scholar101 National Comprehensive Cancer Network: Guidelines for treatment of cancer by site www.nccn.org/professionals/physician_gls/pdf/breast.pdfGoogle ScholarFiguresReferencesRelatedDetailsCited ByPerformance of survivin mRNA as a biomarker for breast cancer among Vietnamese womenBreast Disease, Vol. 5Performance of survivin mRNA as a biomarker for breast cancer among Vietnamese womenHeliyon, Vol. 5, No. 3Herceptin Resistance Database for Understanding Mechanism of Resistance in Breast Cancer Patients27 March 2014 | Scientific Reports, Vol. 4, No. 1High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level12 September 2012 | Breast Cancer, Vol. 21, No. 4Personalized management for breast cancerGeorge C Zografos, Dimosthenis T Chrysikos, Paraskevi Liakou & Flora Zagouri5 December 2011 Vol. 5, No. 1 STAY CONNECTED Metrics Downloaded 659 times History Published online 14 February 2011 Published in print February 2011 Information© Future Medicine LtdKeywordsbreast cancercancer genomecommercializationevidencegeneticsgenomicsinnovationmolecular diagnosticsstandard markertestFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2164701460 created "2016-06-24" @default.
• W2164701460 creator A5046204234 @default.
• W2164701460 creator A5078943260 @default.
• W2164701460 date "2011-02-01" @default.
• W2164701460 modified "2023-09-24" @default.
• W2164701460 title "Innovative biomarker development for personalized medicine in breast cancer care" @default.
• W2164701460 cites W1961026612 @default.
• W2164701460 cites W1965753048 @default.
• W2164701460 cites W1974183735 @default.
• W2164701460 cites W1975060110 @default.
• W2164701460 cites W1980991473 @default.
• W2164701460 cites W1993804787 @default.
• W2164701460 cites W1998108522 @default.
• W2164701460 cites W2016615061 @default.
• W2164701460 cites W2028395388 @default.
• W2164701460 cites W2047031939 @default.
• W2164701460 cites W2051551366 @default.
• W2164701460 cites W2059285082 @default.
• W2164701460 cites W2083374677 @default.
• W2164701460 cites W2092124742 @default.
• W2164701460 cites W2095210116 @default.
• W2164701460 cites W2096250537 @default.
• W2164701460 cites W2097255042 @default.
• W2164701460 cites W2097818804 @default.
• W2164701460 cites W2099356722 @default.
• W2164701460 cites W2105786281 @default.
• W2164701460 cites W2105882193 @default.
• W2164701460 cites W2117540493 @default.
• W2164701460 cites W2117576401 @default.
• W2164701460 cites W2117675709 @default.
• W2164701460 cites W2119279196 @default.
• W2164701460 cites W2121906867 @default.
• W2164701460 cites W2129816567 @default.
• W2164701460 cites W2131597845 @default.
• W2164701460 cites W2135156700 @default.
• W2164701460 cites W2147354890 @default.
• W2164701460 cites W2153565541 @default.
• W2164701460 cites W2155803397 @default.
• W2164701460 cites W2157421521 @default.
• W2164701460 cites W2158734599 @default.
• W2164701460 cites W2160450758 @default.
• W2164701460 cites W2161145860 @default.
• W2164701460 cites W2163347007 @default.
• W2164701460 cites W2187181884 @default.
• W2164701460 cites W2318605753 @default.
• W2164701460 cites W2323044363 @default.
• W2164701460 doi "https://doi.org/10.2217/bmm.10.116" @default.
• W2164701460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21319967" @default.
• W2164701460 hasPublicationYear "2011" @default.
• W2164701460 type Work @default.
• W2164701460 sameAs 2164701460 @default.
• W2164701460 citedByCount "5" @default.
• W2164701460 countsByYear W21647014602012 @default.
• W2164701460 countsByYear W21647014602014 @default.
• W2164701460 countsByYear W21647014602019 @default.
• W2164701460 crossrefType "journal-article" @default.
• W2164701460 hasAuthorship W2164701460A5046204234 @default.
• W2164701460 hasAuthorship W2164701460A5078943260 @default.
• W2164701460 hasConcept C121608353 @default.
• W2164701460 hasConcept C126322002 @default.
• W2164701460 hasConcept C142724271 @default.
• W2164701460 hasConcept C143998085 @default.
• W2164701460 hasConcept C163763905 @default.
• W2164701460 hasConcept C177713679 @default.
• W2164701460 hasConcept C185592680 @default.
• W2164701460 hasConcept C19527891 @default.
• W2164701460 hasConcept C2781197716 @default.
• W2164701460 hasConcept C32220436 @default.
• W2164701460 hasConcept C530470458 @default.
• W2164701460 hasConcept C55493867 @default.
• W2164701460 hasConcept C60644358 @default.
• W2164701460 hasConcept C71924100 @default.
• W2164701460 hasConcept C86803240 @default.
• W2164701460 hasConceptScore W2164701460C121608353 @default.
• W2164701460 hasConceptScore W2164701460C126322002 @default.
• W2164701460 hasConceptScore W2164701460C142724271 @default.
• W2164701460 hasConceptScore W2164701460C143998085 @default.
• W2164701460 hasConceptScore W2164701460C163763905 @default.
• W2164701460 hasConceptScore W2164701460C177713679 @default.
• W2164701460 hasConceptScore W2164701460C185592680 @default.
• W2164701460 hasConceptScore W2164701460C19527891 @default.
• W2164701460 hasConceptScore W2164701460C2781197716 @default.
• W2164701460 hasConceptScore W2164701460C32220436 @default.
• W2164701460 hasConceptScore W2164701460C530470458 @default.
• W2164701460 hasConceptScore W2164701460C55493867 @default.
• W2164701460 hasConceptScore W2164701460C60644358 @default.
• W2164701460 hasConceptScore W2164701460C71924100 @default.
• W2164701460 hasConceptScore W2164701460C86803240 @default.
• W2164701460 hasIssue "1" @default.
• W2164701460 hasLocation W21647014601 @default.
• W2164701460 hasLocation W21647014602 @default.
• W2164701460 hasOpenAccess W2164701460 @default.
• W2164701460 hasPrimaryLocation W21647014601 @default.
• W2164701460 hasRelatedWork W2050875047 @default.
• W2164701460 hasRelatedWork W2296863086 @default.
• W2164701460 hasRelatedWork W2339025832 @default.
• W2164701460 hasRelatedWork W2909399418 @default.

• next